FORM OF INDEMNIFICATION AGREEMENTForm of Indemnification Agreement • August 7th, 2017 • Molecular Templates, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [•], 2017 by and between Molecular Templates, Inc., (formerly, Threshold Pharmaceuticals, Inc.) a Delaware corporation (the “Company”), and [•] (the “Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.
MULTI-TARGET COLLABORATION AND LICENSE AGREEMENT Between MOLECULAR TEMPLATES, INC. and MILLENNIUM PHARMACEUTICALS, INC. Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and...License Agreement • August 7th, 2017 • Molecular Templates, Inc. • Pharmaceutical preparations • Massachusetts
This Multi-Target Collaboration and License Agreement (this “Agreement”) is entered into as of June 23, 2017 (the “Effective Date”) by and between MOLECULAR TEMPLATES, INC., a Delaware corporation, having its principal place of business at 9301 Amberglen Boulevard, Suite 100, Austin, TX 78729 (“MTEM”) and MILLENNIUM PHARMACEUTICALS, INC., a Delaware corporation, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, having its principal place of business at 40 Landsdowne Street, Cambridge, MA 02139 (“Takeda”). MTEM and Takeda may sometimes individually be referred to hereafter as a “Party” or collectively as the “Parties.”
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 7th, 2017 • Molecular Templates, Inc. • Pharmaceutical preparations • Delaware
This Registration Rights Agreement (the “Agreement”) is made and entered into as of August 1, 2017 by and among Molecular Templates, Inc. (which name, prior to the closing of the Merger, was Threshold Pharmaceuticals, Inc.), a Delaware corporation (the “Company”), the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors of even date herewith (the “Securities Purchase Agreement”) and Millennium Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd. (“Millennium”). The Company and the Investors may each be referred to herein individually as a “Party” and collectively as the “Parties.” This Agreement is made pursuant to the Securities Purchase Agreement and the Stock Purchase Agreement by and among the Company and Millennium of even date herewith (together with the Securities Purchase Agreement, the “Purchase Agreements”) and shall be effective as of the Closing. Capitalized te
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 7th, 2017 • Molecular Templates, Inc. • Pharmaceutical preparations • Delaware
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made as of August 1, 2017 (the “Effective Date”) by and among Molecular Templates, Inc. (which name, prior to the closing of the Merger, was Threshold Pharmaceuticals, Inc.), a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, identified as an Investor on the Schedule of Investors attached as Exhibit A hereto (the “Schedule of Investors”). Such persons and entities together with their permitted successors and assigns, are referred to collectively as the “Investors” and each individually as an “Investor”. The Company and the Investors may each be referred to herein individually as a “Party” and collectively as the “Parties.”
